CIRCULATING plasma tau fragments provide a promising CTE blood biomarker for identifying severe neuropathologic changes antemortem. Two paired clinical neuropathology studies demonstrate that endogenously cleaved microtubule-binding region tau (eMTBR-tau) and its residue 243 species (eMTBR-tau243) distinguish advanced chronic traumatic encephalopathy from cognitively unimpaired controls. Because definitive diagnosis currently relies on postmortem examination of perivascular phosphorylated tau aggregates, validated fluid diagnostics represent a critical step toward earlier clinical recognition and targeted trial enrollment.
Evaluating a Novel CTE Blood Biomarker
In a clinicopathologic case series of 21 former male American-style football players who donated their brains, investigators measured antemortem plasma eMTBR-tau alongside plasma phosphorylated tau 217 (p-tau217). Among 18 donors with autopsy-confirmed disease, median plasma eMTBR-tau concentrations were markedly higher in high-stage pathology (stages III and IV, 0.021 pg/mL) than in low-stage disease (stages I and II, 0.001 pg/mL) or absent pathology (0.001 pg/mL). Elevated eMTBR-tau also correlated strongly with cumulative neuropathologic tau burden across 11 brain regions, and these associations persisted after excluding five individuals with comorbid Alzheimer disease neuropathologic change.
Distinguishing Mixed Tauopathies in Clinical Practice
A complementary multicenter case-control investigation evaluated cerebrospinal fluid and plasma eMTBR-tau243 across 229 participants with diverse neurodegenerative conditions. Concentrations rose specifically in mixed 3-repeat and 4-repeat tauopathies, including Alzheimer disease, late-stage chronic traumatic encephalopathy, and symptomatic frontotemporal lobar degeneration linked to select MAPT variants, whereas primary 3-repeat or 4-repeat tauopathies showed no elevation. In plasma analyses, eMTBR-tau243 discriminated stage III and IV trauma-related pathology from controls with an area under the curve of 0.97, though neither assay reliably detected stage I disease.
Implications for Diagnosis and Trials
Clinically, pairing this CTE blood biomarker with amyloid-sensitive markers could clarify differential diagnoses in patients with repetitive head impact exposure. While concurrent elevations in eMTBR-tau and p-tau217 point toward Alzheimer disease or mixed copathology, elevated eMTBR-tau accompanied by negative or intermediate p-tau217 suggests isolated late-stage trauma-related tauopathy. Larger longitudinal cohorts are still needed to establish diagnostic thresholds and validate utility across broader populations, including female athletes and military personnel.
Reference
Miner AE et al. Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology. JAMA. 2026;doi:10.1001/jama.2026.24780.
Horie K et al. Fluid eMTBR-tau243 as a biomarker of mixed 3-repeat and 4-repeat tau pathology. JAMA. 2026;doi:10.1001/jama.2026.24689.